GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Lilly Glucagon

Company
Xeris Pharmaceuticals
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT01972152

    Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia

    Not yet reported Xeris Pharmaceuticals 30 participants Est. completion 2014-02 1 site Stand-alone
    Other conditions: Hypoglycemia
    View official trial listing →
  • Completed NCT NCT02018627

    Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon

    Not yet reported, Not yet reported Steven J. Russell, MD, PhD 20 participants Est. completion 2018-08-02 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT02403648

    Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons

    Not yet reported Biodel 15 participants
    Other conditions: Hypoglycemia
    View official trial listing →
  • Completed NCT NCT02656069

    Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics

    Not yet reported Xeris Pharmaceuticals 80 participants Est. completion 2017-09-25 7 sites
    Other conditions: Hypoglycemia, Diabetes Mellitus, Type 1
    View official trial listing →
  • Terminated NCT NCT02701257

    The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas

    Not yet reported Massachusetts General Hospital 20 participants Est. completion 2018-05 1 site Stand-alone
    Other conditions: Diabetes Mellitus Type 1
    View official trial listing →
  • Completed NCT NCT02916251

    ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon

    Not yet reported Zealand Pharma 38 participants Est. completion 2017-04-05 1 site
    Other conditions: Diabetes Mellitus Type 1
    View official trial listing →
  • Completed NCT NCT02971228

    Feasibility Trial Testing the Bionic Pancreas With ZP4207

    Not yet reported Zealand Pharma 13 participants Est. completion 2017-06-07 1 site Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT03439072

    G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes

    Not yet reported Xeris Pharmaceuticals 81 participants Est. completion 2018-05-03 6 sites
    Other conditions: Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.